{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T14:29:03Z","timestamp":1777127343052,"version":"3.51.4"},"reference-count":4,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":368,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ymthe.2020.10.002","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T09:11:53Z","timestamp":1602234713000},"page":"2303-2304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Pros and Cons of Adenovirus-Based SARS-CoV-2 Vaccines"],"prefix":"10.1016","volume":"28","author":[{"given":"Eric J.","family":"Kremer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2020.10.002_bib1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.coviro.2018.12.004","article-title":"Emergence and re-emergence of respiratory adenoviruses in the United States","volume":"34","author":"Kajon","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ymthe.2020.10.002_bib2","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/14760584.2019.1588113","article-title":"A review of 65 years of human adenovirus seroprevalence","volume":"18","author":"Mennechet","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ymthe.2020.10.002_bib3","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1473-3099(14)70020-9","article-title":"Recombinant adenovirus type 5 HIV gag\/pol\/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503\/Phambili study","volume":"14","author":"Gray","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2020.10.002_bib4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.immuni.2020.07.005","article-title":"Lessons for COVID-19 Immunity from Other Coronavirus Infections","volume":"53","author":"Sariol","year":"2020","journal-title":"Immunity"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620305360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620305360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:58:20Z","timestamp":1761501500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001620305360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":4,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1525001620305360"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.10.002","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pros and Cons of Adenovirus-Based SARS-CoV-2 Vaccines","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}